Aktis Oncology, Inc. (AKTS)
Aktis Oncology develops radiopharmaceutical cancer treatments that deliver radioactive material directly to tumors. It last closed at $16.31 on Nov 17, up 0.93% on the day. The average 12-month price target from 2 analysts is $37.50 (+129.9% from the last close), with a high of $40.00 and a low of $35.00.
Analyst Ratings & Price Targets
Analyst Ratings →Based on 2 analysts who set a price target on AKTS in the past 90 days. The average target is $37.50, with a high of $40.00 and a low of $35.00, compared with the last close of $16.31.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 2 | Wedbush | Reiterated | Buy | $35 |
| Sep 9 | Oppenheimer | Initiated | Buy | $40 |
| Aug 19 | Wedbush | Initiated | Buy | $35 |
| Aug 19 | BMO Capital | Initiated | Buy | $37 |
| Jul 14 | JP Morgan | Maintained | Buy | $33 |
Technical Analysis
The stock sits between its 20 and 50 day averages. It is 27% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 47). The nearest support is the 20 day average at $16.12, and the nearest resistance the Pivot R1 at $16.65.
| RSI (14) | 46.71 | Middle of its range | Neutral |
| MACD | -0.43 | Above its signal line | Bullish |
| Stochastic | 61.1 | Middle of its range | Neutral |
| ADX (14) | 22.4 | Weak trend | |
| Williams %R | -40.3 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 2.5 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | +9.2% | Change over 10 sessions | Bullish |
| ATR (14) | $1.02 | Typical daily range, 6.3% of price |
| RSI (14) | 39.14 | Weak, oversold below 30 | Neutral |
| MACD | -1.48 | Below its signal line | Bearish |
| Stochastic | 16.5 | Near the bottom of its range | Oversold |
| ADX (14) | 19.4 | No clear trend | |
| Williams %R | -83.1 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -86.8 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −30.0% | Change over 10 sessions | Bearish |
| ATR (14) | $2.92 | Typical daily range, 17.9% of price |
What happened before
See how AKTS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Whale Options Flow
90DNo whale options trades in AKTS in the last 90 days.
AKTS Institutional Ownership
Full report →- ▲84 buying vs 41 selling
- ▲Shares held by funds +7.7%
- ▲Funds holding +11
- ▲Superinvestors: 3 added, 2 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 125 | 114 | +9.6% |
| In funds' top 10 | 5 | 5 | 0.0% |
| Held by funds | – | – | – |
| New / increased | 30 / 54 | 51 / 27 | +7.7% |
| Reduced / sold out | 23 / 18 | 18 / 6 | +70.8% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AKTS is in one of them and how their past AKTS trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered AKTS in an article yet. Here's the latest on the wider market.
About Aktis Oncology
Aktis Oncology is a company based in Boston that develops radiopharmaceuticals, which are cancer treatments that carry radioactive material directly to tumors. Its main focus is a platform built on small engineered proteins that bind to targets on cancer cells. Its lead candidate targets Nectin-4, a protein found on several solid tumor types, and is being tested in clinical trials for urothelial cancer and other tumors. The company works with isotope suppliers and contract manufacturers to supply these treatments to cancer patients and their doctors.
- Headquarters
- Boston, MA




